MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1
Corresponding Author
Takehiko Yokobori
Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan
To whom correspondence should be addressed.
E-mail: [email protected]
Search for more papers by this authorShigemasa Suzuki
Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this authorNaritaka Tanaka
Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this authorTakanori Inose
Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this authorMakoto Sohda
Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this authorAkihiko Sano
Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this authorMakoto Sakai
Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this authorMasanobu Nakajima
First Department of Surgery, Dokkyo Medical University, Shimotsuga-gun, Tochigi, Japan
Search for more papers by this authorTatsuya Miyazaki
Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this authorHiroyuki Kato
First Department of Surgery, Dokkyo Medical University, Shimotsuga-gun, Tochigi, Japan
Search for more papers by this authorHiroyuki Kuwano
Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this authorCorresponding Author
Takehiko Yokobori
Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan
To whom correspondence should be addressed.
E-mail: [email protected]
Search for more papers by this authorShigemasa Suzuki
Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this authorNaritaka Tanaka
Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this authorTakanori Inose
Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this authorMakoto Sohda
Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this authorAkihiko Sano
Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this authorMakoto Sakai
Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this authorMasanobu Nakajima
First Department of Surgery, Dokkyo Medical University, Shimotsuga-gun, Tochigi, Japan
Search for more papers by this authorTatsuya Miyazaki
Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this authorHiroyuki Kato
First Department of Surgery, Dokkyo Medical University, Shimotsuga-gun, Tochigi, Japan
Search for more papers by this authorHiroyuki Kuwano
Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan
Search for more papers by this authorAbstract
The association of microRNAs (miRs) with cancer progression has been established in many cancers including esophageal squamous cell carcinoma (ESCC). A public microarray database showed that the expression of miR-150 was lower in ESCC than in normal esophageal mucosa. Here, we focused on ZEB1, epithelial-mesenchymal-transition (EMT)-inducer, as a target gene of miR-150 based on in silico predictions. The purpose of this study was to clarify the clinicopathological significance of miR-150 in ESCC, and to investigate miR-150′s EMT-regulatory ability. Quantitative RT-PCR was used to evaluate miR-150 expression in 108 curative resected ESCC samples to determine the clinicopathological significance. Moreover, we examined the in vitro and in vivo function of miR-150 via degradation of ZEB1. MiR-150 expression was significantly lower in cancer tissues compared to adjacent non-cancerous tissues (P < 0.001). Low expression of miR-150 in ESCC contributed to malignant potential, such as tumor depth, lymph node metastasis, lymphatic invasion, venous invasion, clinical staging, and poor prognosis (P < 0.05). In vitro assays showed that EMT-inducer-ZEB1 is a new direct target of miR-150. Moreover, miR-150 induced MET-like changes in TE-8 cells through ZEB1 degradation (e.g., E-cadherin expression, vimentin repression, epithelial morphology, and suppression of migration ability), and significantly inhibited tumorigenicity and tumor growth in a mouse xenograft model. Analysis of the regulation of ZEB1 by miR-150 could provide new insights into preventing metastasis and also suggests novel targeted therapeutic strategies in ESCC. (Cancer Sci 2013; 104: 48–54)
Supporting Information
Filename | Description |
---|---|
cas12030-sup-0001-FigS1.TIFimage/TIF, 148.4 KB | Fig. S1. Re-analysis of microarray database GSE6188. |
cas12030-sup-0002-FigS2.TIFimage/TIF, 306.4 KB | Fig. S2. Proliferation and migration were upregulated in TE-15 cells treated with an miR-150 inhibitor. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Malthaner RA, Wong RK, Rumble RB, Zuraw L. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2004; 2: 35.
- 2Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226–34.
- 3Tepper J, Krasna MJ, Niedzwiecki D et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086–92.
- 4Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349: 2241–52.
- 5Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108.
- 6Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006; 20: 515–24.
- 7Guo Y, Chen Z, Zhang L et al. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 2008; 68: 26–33.
- 8Kong KL, Kwong DL, Chan TH et al. microRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2012; 61: 33–42.
- 9Watanabe A, Tagawa H, Yamashita J et al. The role of microRNA-150 as a tumor suppressor in malignant lymphoma. Leukemia 2011; 25: 1324–34.
- 10Agirre X, Jimenez-Velasco A, San Jose-Eneriz E et al. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res 2008; 6: 1830–40.
- 11Zhao JJ, Lin J, Lwin T et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010; 115: 2630–9.
- 12Amaral FC, Torres N, Saggioro F et al. microRNAs differentially expressed in ACTH-secreting pituitary tumors. J Clin Endocrinol Metab 2009; 94: 320–3.
- 13Lulla RR, Costa FF, Bischof JM et al. Identification of Differentially Expressed microRNAs in Osteosarcoma. Sarcoma 2011; 2011: 732690.
- 14Xiao C, Calado DP, Galler G et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 2007; 131: 146–59.
- 15Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev Cancer 2008; 8: 523–34.
- 16Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265–73.
- 17Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704–15.
- 18Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop–a motor of cellular plasticity in development and cancer? EMBO Rep 2010; 11: 670–7.
- 19Korpal M, Kang Y. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 2008; 5: 115–9.
- 20Usami Y, Satake S, Nakayama F et al. Snail-associated epithelial-mesenchymal transition promotes oesophageal squamous cell carcinoma motility and progression. J Pathol 2008; 215: 330–9.
- 21Suzuki S, Miyazaki T, Tanaka N et al. Prognostic significance of CD151 expression in esophageal squamous cell carcinoma with aggressive cell proliferation and invasiveness. Ann Surg Oncol 2011; 18: 888–93.
- 22Chen ML, Liang LS, Wang XK. miR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1. Clin Exp Metastasis 2012; 29: 457–69.
- 23Ohashi S, Natsuizaka M, Wong GS et al. Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res 2010; 70: 4174–84.
- 24Wellner U, Schubert J, Burk UC et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11: 1487–95.
- 25Korpal M, Ell BJ, Buffa FM et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 2011; 17: 1101–8.
- 26Thompson EW, Haviv I. The social aspects of EMT-MET plasticity. Nat Med 2011; 17: 1048–9.
- 27Ghisi M, Corradin A, Basso K et al. Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood 2011; 117: 7053–62.
- 28Tano N, Kim HW, Ashraf M. microRNA-150 regulates mobilization and migration of bone marrow-derived mononuclear cells by targeting Cxcr4. PLoS ONE 2011; 6: e23114.
- 29Davis ME, Zuckerman JE, Choi CH et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464: 1067–70.
- 30Soifer HS, Rossi JJ, Saetrom P. microRNAs in disease and potential therapeutic applications. Mol Ther 2007; 15: 2070–9.
- 31Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011; 11: 59–67.
- 32Elmen J, Lindow M, Schutz S et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452: 896–9.
- 33Silvestri P, Di Russo C, Rigattieri S et al. microRNAs and ischemic heart disease: towards a better comprehension of pathogenesis, new diagnostic tools and new therapeutic targets. Recent Pat Cardiovasc Drug Discov 2009; 4: 109–18.